Biodesix, Inc. (BDSX)

Biodesix, Inc. is a leading biotechnology company specializing in the development of diagnostic solutions for lung disease, with a strong focus on precision medicine and personalized healthcare. Founded in 2005 by David Brunel and John Patience, Biodesix aims to improve patient outcomes by offering innovative blood-based tests that provide actionable insights to guide treatment decisions, particularly in oncology. The company is renowned for its unique approach that integrates genomics and proteomics to develop non-invasive diagnostic tools. Biodesix is headquartered in Boulder, Colorado, and has built a reputation for its commitment to advancing lung cancer care. Their flagship products, such as VeriStrat® and Nodify XL2®, are designed to support physicians in making more informed clinical decisions. As of the latest financial reports, Biodesix continues to experience growth, reflecting an increasing demand for precision diagnostics in the healthcare industry.